Immune checkpoint inhibitors are a class of drugs used in cancer treatment that promote the immune system’s response by blocking the inhibitor signals from tumour cells, such as programmed cell death protein 1/programmed death ligand 1 and cytotoxic T-lymphocyte associated protein 4. Here, CTLA4 is linked to cancer.